MedPath

Effects of anagliptin/metformin combination tablets: a retrospective observational study

Not Applicable
Conditions
Type 2 diabetes mellitus
Registration Number
JPRN-UMIN000041979
Lead Sponsor
Fukuda Clinic
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
90
Inclusion Criteria

Not provided

Exclusion Criteria

1. Patients who received antidiabetic drugs for less than 8 weeks before switch to anagliptin / metformin hydrochloride combination tablets 2. Patients who denied the use of clinical medical records to the study

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Change in HbA1c
Secondary Outcome Measures
NameTimeMethod
1.Change in LDL-C 2.Change in HDL-C 3.Change in eGFR 4.Change in body weight, BMI and body composition 5.Incidence of adverse events
© Copyright 2025. All Rights Reserved by MedPath